When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit the ...

Back to college usually means meningitis vaccine marketing, and that's exactly what GlaxoSmithKline is doing. It recently boosted its meningitis B awareness push with a second animated commercial ...

GSK said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product lineup. Walmsley will step down at the end of ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK on Monday said that ...

GSK said Emma Walmsley would step down after more than eight years as chief executive and named its commercial chief, Luke Miels, to succeed her in the top job. Walmsley, who became CEO of the U.K.